Regeneron Granted FDA Emergency Use Authorization for its COVID-19 Antibody Cocktail Therapy

Regeneron Pharmaceuticals Receives EUA from the FDA for REGEN-COV2
Regeneron Pharmaceuticals’ (REGN) antibody cocktail therapy casirivimab and imdevimab, known also REGN-COV2 or REGEN-COV2, received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA).

The FDA EUA is for the treatment of mild to moderate COVID-19 in adults as well as pediatric patients at least 12 years of age and weighing at least 40 kg who have received positive results of direct SARS-CoV-2 (the virus that causes COVID-19) viral testing . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.